EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Hidradenitis suppurativa in Malaysia: Expert consensus on diagnosis, management, and therapeutic strategies

Azura Mohd Affandi, Sook Yee Michelle Voo, Pubalan Muniandy, Felix Boon-Bin Yap, Wooi Chiang Tan, Peter Wee Beng Ch’ng, Norazirah Md Nor, Chin Chwen Ch’ng, Evelyn Wen Yee Yap, Latha R. Selvarajah, Teeba Raja, Shin Shen Yong und 1 weitere

Dermatologica Sinica · 2026-04 · 44 (2) · 99-109

DOI: 10.4103/ds.ds-d-25-00153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologica Sinica, online erschienen am 30.06.2026. Verfasst von Azura Mohd Affandi und 12 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin disorder, affecting intertriginous areas and characterized by painful nodules, abscesses, fistulae, and scarring. Despite its impact on patients’ quality of life (QoL), HS remains underdiagnosed and mismanaged due to its heterogeneous clinical presentation. A panel of 14 Malaysian dermatologists, HS special interest group, developed a set of consensus-based recommendations on diagnosis, disease assessment, comorbidities, treatment, and follow-up care to improve HS management. A modified Delphi process was utilized to draft and finalize statements based on evidence sourced from literature between 2013 and 2023. The consensus highlights the importance of early recognition of HS clinical signs, differential diagnosis, and the use of validated tools such as Hurley staging, International HS Severity Score System, and Dermatology Life Quality Index to assess disease severity and QoL. Treatment recommendations for HS were stratified by disease severity, including topical, systemic, and biologic therapies, and surgical interventions for advanced cases. Adalimumab and secukinumab are currently the only approved biologics in Malaysia, showing sustained efficacy in moderate-to-severe HS. Adjunctive therapies such as zinc supplementation, lifestyle modifications, and wound care are also recommended. The consensus emphasizes a multidisciplinary approach to address the multifaceted nature of HS and optimize long-term outcomes, and aims to standardize HS care in Malaysia, promote early intervention, and enhance QoL for affected patients.

Zitieren

APA

Affandi, A. M., Voo, S. Y. M., Muniandy, P., Yap, F. B., Tan, W. C., Ch’ng, P. W. B., Nor, N. M., Ch’ng, C. C., Yap, E. W. Y., Selvarajah, L. R., Raja, T., Yong, S. S., & Tang, J. J. (2026). Hidradenitis suppurativa in Malaysia: Expert consensus on diagnosis, management, and therapeutic strategies. Dermatologica Sinica, 44(2), 99-109. https://doi.org/10.4103/ds.ds-d-25-00153

Vancouver

Affandi AM, Voo SYM, Muniandy P, Yap FB, Tan WC, Ch’ng PWB, et al. Hidradenitis suppurativa in Malaysia: Expert consensus on diagnosis, management, and therapeutic strategies. Dermatologica Sinica. 2026;44(2):99-109. doi:10.4103/ds.ds-d-25-00153

BibTeX
@article{Affandi2026,
  author = {Affandi, Azura Mohd and Voo, Sook Yee Michelle and Muniandy, Pubalan and Yap, Felix Boon-Bin and Tan, Wooi Chiang and Ch’ng, Peter Wee Beng and Nor, Norazirah Md and Ch’ng, Chin Chwen and Yap, Evelyn Wen Yee and Selvarajah, Latha R. and Raja, Teeba and Yong, Shin Shen and Tang, Jyh Jong},
  title = {Hidradenitis suppurativa in Malaysia: Expert consensus on diagnosis, management, and therapeutic strategies},
  journal = {Dermatologica Sinica},
  year = {2026},
  volume = {44},
  number = {2},
  pages = {99--109},
  doi = {10.4103/ds.ds-d-25-00153}
}
Kostenlos starten →